When, how, and why should sinus Rhythm be restored in patients with persistent atrial fibrillation?
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
The results of the AFFIRM (Atrial Fibrillation Follow-up Investigation of Rhythm Management) trial indicate that the rate control strategy is preferred for the majority of patients with paroxysmal and persistent atrial fibrillation (AF). If the patient remains symptomatic despite adequate rate control or if rate control cannot be achieved, then rhythm control therapies are indicated. The most likely explanation for the disappointing results of the AFFIRM trial is the poor efficacy and excessive toxicity of rhythm control medications, because the presence of sinus rhythm was associated with a favorable prognosis in AFFIRM. As a result, there is currently great interest in nonpharmacologic therapies such as AF ablation and development of new drugs for AF with a more favorable efficacy and toxicity profile. AF ablation should be reserved for patients who fail an initial trial of a rhythm control medication until additional clinical trial information is available to justify the use of AF ablation as first-line therapy. When rhythm control therapy is indicated, the choice of antiarrhythmic medication should be dictated by the presence or absence of structural heart disease, congestive heart failure, renal dysfunction, or other comorbidities in order to maximize efficacy and minimize the chance of proarrhythmia or extracardiac toxicity.
- Ali S, Hong M, Antezano ES, Mangat I: Evaluation and management of atrial fibrillation. Cardiovasc Hematol Disord Drug Targets 2006, 6:233–244.
- Geraets DR, Kienzle MG: Atrial fibrillation and atrial flutter. Clin Pharm 1993, 12:721–735.
- Feinberg WM, Blackshear JL, Laupacis A, et al.: Prevalence, age distribution, and gender of patients with atrial fibrillation: analysis and implications. Arch Intern Med 1995, 155:469–473. CrossRef
- Go AS, Hylek EM, Phillips KA, et al.: Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001, 285:2370–2375. CrossRef
- Wolf PA, Abbott RD, Kannel WB: Atrial fibrillation: a major contributor to stroke in the elderly: the Framingham Study. Arch Intern Med 1987, 147:1561–1564. CrossRef
- Crenshaw BS, Ward SR, Granger CB, et al.: Atrial fibrillation in the setting of acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. J Am Coll Cardiol 1997, 30:406–413 CrossRef
- Dries DL, Exner DV, Gersh BJ, et al.: Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 1998, 32:695–703. CrossRef
- Wyse DG, Waldo AL, DiMarco JP, et al.: A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002, 347:1825–1833. CrossRef
- Hohnloser SH, Kuck KH, Lilienthal J: Rhythm or rate control in atrial fibrillation—Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomized trial. Lancet 2000, 356:1789–1794. CrossRef
- Carlsson J, Miketic S, Windeleer J, et al.: Randomized trial of rate control versus rhythm control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol 2003, 41:1690–1696. CrossRef
- Van Gelder IC, Hagens VE, Bosker HA, et al.: A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002, 347:1834–1840. CrossRef
- Opolski G, Torbicki A, Kosior DA, et al.: Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study. Chest 2004, 126:476–486. CrossRef
- Marshall DA, Levy AR, Vidaillet H, et al.: Cost-effectiveness of rhythm versus rate control in atrial fibrillation. Ann Intern Med 2004, 141:653–661.
- Relationship between sinus rhythm, treatment and survival in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study [no authors listed]. Circulation 2004, 109:1509–1513.
- Haïssaguerre M, Jaïs P, Shah DC, Takahashi A, et al.: Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998, 339:659–666. CrossRef
- Pappone C, Oreto G, Rosanio S, et al.: Atrial electroanatomic remodeling after circumferential radiofrequency pulmonary vein ablation: efficacy of an anatomic approach in a large cohort of patients with atrial fibrillation. Circulation 2001, 104:2539–2544. CrossRef
- Nademanee K, McKenzi J, Kosar E, et al.: A new approach for catheter ablation of atrial fibrillation: mapping of the electrophysiologic substrate. J Am Coll Cardiol 2004, 43:2044–2053. CrossRef
- Pappone C, Santinelli V, Manguso F, et al.: Pulmonary vein denervation enhances long-term benefit after circumferential ablation for paroxysmal atrial fibrillation. Circulation 2004, 109:327–334. CrossRef
- European Heart Rhythm Association (EHRA); European Cardiac Arrhythmia Scoiety (ECAS); American College of Cardiology (ACC); American Heart Association (AHA); Society of Thoracic Surgeons (STS), et al.: HRS/EHRA/ECAS expert Consensus Statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) Task Force on catheter and surgical ablation of atrial fibrillation. Heart Rhythm 2007, 4:816–861. CrossRef
- Hsu LF, Jais P, Sanders P, et al.: Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med 2004, 351:2373–2783. CrossRef
- Cappato R, Calkins H, Chen SA, et al.: Worldwide survey of the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circulation 2005, 111:1100–1105. CrossRef
- Olshansky B, Rosenfeld LE, Warner AL, et al.: The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: approaches to control rate in atrial fibrillation. J Am Coll Cardiol 2004, 43:1201–1208. CrossRef
- Volgman AS, Carberry PA, Stambler B, et al.: Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation. J Am Coll Cardiol 1998, 31:1414–1419. CrossRef
- Lown B, Perlroth MG, Kaidbey S, et al.: Cardioversion of atrial fibrillation. N Engl J Med 1963, 269:325–331. CrossRef
- Morris JJ, Peter RH, McIntosh HD: Electrical conversion of atrial fibrillation. Immediate and long-term results of and selection of patients. Ann Intern Med 1966, 65:216.
- Rashba EJ, Bouhouch R, Koshy S, et al.: A new algorithm for transthoracic cardioversion of atrial fibrillation based on body weight. Am J Cardiol 2001, 88:1043–1045. CrossRef
- Kawabata VS, Vianna CB, Moretti MA, et al.: Monophasic versus biphasic waveform shocks for atrial fibrillation cardioversion in patients with concomitant amiodarone therapy. Europace 2007, 9:143–146. CrossRef
- Boriani G, Biffi M, Cervi V, et al.: Evaluation of myocardial injury following repeated internal atrial shocks by monitoring serum cardiac troponin I levels. Chest 2000, 118:342–347. CrossRef
- Page RL, Kerber RE, Russell JK, et al.: Biphasic versus monophasic shock waveform for conversion of atrial fibrillation: the results of an international randomized, double-blind multicenter trial. J Am Coll Cardiol 2002, 39:1956–1963. CrossRef
- Mittal S, Ayat S, Stein K.M, et al.: Transthoracic cardioversion of atrial fibrillation comparison of rectilinear biphasic versus damped sine wave monophasic shocks. Circulation 2000, 101:1282–1287.
- Lown B: Electrical reversion of cardiac arrhythmias. Br Heart J 1967, 29:469–489. CrossRef
- Kirchhof P, Eckardt L, Loh P, et al.: Anterior-posterior vs. anterior-lateral electrode positions for external cardioversion of atrial fibrillation: a randomized trial. Lancet 2002, 360:1275–1279. CrossRef
- Botto GL, Politi A, Bonini W, et al.: External cardioversion of atrial fibrillation: role of paddle position on technical efficacy and energy requirements. Heart 1999, 82:726–730.
- Kirchhof P, Mönnig G, Wasmer K, et al.: A trial of self-adhesive patch electrodes and hand-held paddle electrodes for external cardioversion of atrial fibrillation (MOBIPAPA). Eur Heart J 2005, 26:1292–1297. CrossRef
- Rashba EJ, Gold MR, Crawford FA, et al.: Efficacy of transthoracic cardioversion of atrial fibrillation using a biphasic, truncated exponential shock waveform at variable initial shock energies. Am J Cardiol 2004, 94:1572–1574. CrossRef
- Oral H, Souza JJ, Michaud GF, et al.: Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment. N Engl J Med 1999, 340:1849–1854. CrossRef
- Rashba EJ, Shorofsky SR, Peters RW, et al.: Optimization of atrial defibrillation with a dual-coil, active pectoral lead system. J Cardiovasc Electrophysiol 2004, 15:790–794. CrossRef
- Rashba EJ, Shorofsky SR, Scheiner A, et al.: Coronary sinus electrode does not reduce atrial defibrillation thresholds. Heart Rhythm 2006, 3:647–652. CrossRef
- European Heart Rhythm Association; Heart Rhythm Society; et al.: ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: executive summary. a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol 2006, 48:854–906. CrossRef
- Rx List: 2007 Corvert (Ibutilide). Available at it http://www.rxlist.com/cgi/generic/ibutilide.htm. Accessed May 1, 2007.
- Julian DG, Camm AJ, Frangin G, et al.: Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. Lancet 1997, 349:667–674. CrossRef
- Kober L, Bloch Thomsen PE, Moller M, et al.: Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomised trial. Danish Investigators of Arrhythmia and Mortality on Dofetilide (DIAMOND). Lancet 2000, 356:2052–2058. CrossRef
- When, how, and why should sinus Rhythm be restored in patients with persistent atrial fibrillation?
Current Treatment Options in Cardiovascular Medicine
Volume 9, Issue 5 , pp 372-378
- Cover Date
- Print ISSN
- Online ISSN
- Current Science Inc.
- Additional Links